Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JSKN 016

Next Previous
Drug Profile

JSKN 016

Alternative Names: JSKN-016

Latest Information Update: 13 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab Oncology
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Jun 2025 Phase-I/II clinical trials in HER2-negative-breast-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV) (NCT06942234)
  • 30 May 2025 Efficacy, adverse event and pharmacokinetics data from a phase I trial in Solid tumour presented at the 61st Annual Meeting of the American Society of Clinical Oncology 2025 (ASCO-2025)
  • 30 Apr 2025 Jiangsu Alphamab Biopharmaceuticals plans a phase I/II trial for HER2-negative breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/unresectable) (IV, Infusion), in June 2025 (NCT06942234)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top